Published: Tue, September 12, 2017
Business | By Max Garcia

Wells Fargo & Company MN Trims Position in Alexion Pharmaceuticals, Inc. (ALXN)

Wells Fargo & Company MN Trims Position in Alexion Pharmaceuticals, Inc. (ALXN)

Alexion also plans to relocate its headquarters from New Haven, Conn.to Boston, joining General Electric Co. and Aetna Inc. announcing plans to move its headquarters out of the state in recent years. (NASDAQ:ALXN) traded down -1.61% in the last session while performance was up 141.19% in the last five days. Willis Investment Counsel acquired 2,900 shares as United Parcel Service (UPS)'s stock declined 3.26%. Royal Bank Of Canada owns 0.01% invested in Alexion Pharmaceuticals, Inc.

Sept 12 (Reuters) - Alexion Pharmaceuticals Inc said on Tuesday it would lay off about 20 percent of its workforce and sharpen its focus on its core rare disease drugs business, as it looks to restore investor confidence. Rockefeller Svcs accumulated 9,257 shares or 0.02% of the stock. Jennison Associates LLC raised its position in shares of Alexion Pharmaceuticals by 0.6% in the third quarter.

Apple Inc. most recently reported earnings per share (EPS) of $1.67 for the June 2017 versus $1.42 in the same quarter a year ago, representing 18% growth.

07/13/2017 - Alexion Pharmaceuticals, Inc. had its "buy" rating reiterated by analysts at SunTrust. Neuberger Berman Group LLC now owns 272,363 shares of the biopharmaceutical company's stock worth $33,138,000 after acquiring an additional 266,174 shares during the last quarter. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34. Moreover, Blackrock Fund Advsr has 0.12% invested in Alexion Pharmaceuticals, Inc.

In pre-market trading, Alexion shares were up 1.5% at US$142.93. Pacer Advisors Inc. now owns 6,742 shares of the biopharmaceutical company's stock worth $820,000 after acquiring an additional 465 shares during the last quarter. The company's 50 day moving average price is $136.89 and its 200 day moving average price is $124.25. The company has market cap of $31.89 billion. Sumitomo Mitsui Asset Mngmt reported 0.04% in Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, July 27th. The company's quarterly EPS surprised Wall Street by as much as 6% to the upside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates. The business had revenue of $912 million during the quarter, compared to analysts' expectations of $846.15 million. $234,200 worth of Alexion Pharmaceuticals, Inc.

This move comes after Alexion laid off 210 employees company-wide in March 2017.

At the end of past year, the company had 3,121 employees across seven locations around the world.

Howard Hughes Medical Institute decreased Twenty First Centy Fox Inc (FOXA) stake by 45.03% reported in 2016Q4 SEC filing. J P Morgan Chase & Co cut Alexion Pharmaceuticals from an "overweight" rating to a "neutral" rating in a research report on Tuesday, May 23rd. Alexion Pharmaceuticals Inc. had 71 analyst reports since July 27, 2015 according to SRatingsIntel.

Alexion's decision to move their headquarters out of New Haven is shocking and shameful. Raymond James initiated it with "Strong Buy" rating and $225.0 target in Tuesday, September 1 report. The stock now has an average rating of "Buy" and a consensus target price of $156.32. Jennison Associates LLC now owns 7,137,235 shares of the biopharmaceutical company's stock valued at $874,597,000 after buying an additional 43,840 shares during the last quarter. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction on Monday, July 31st. The shares were sold on August 28th for an average price of $140.00. The institutional investor held 795,905 shares of the health care company at the end of 2016Q4, valued at $97.38M, up from 764,005 at the end of the previous reported quarter. The disclosure for this purchase can be found here. Asset Incorporated invested in 0.04% or 17,462 shares. 99,710 are owned by Lmm Ltd Limited Liability Company. Rainier Inv Management Ltd Liability Com has invested 0.39% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). EVP Julie O'neill sold 4,375 shares at a price of $145.25 on September 5th. If you are accessing this article on another website, it was illegally copied and republished in violation of USA and worldwide trademark and copyright legislation.

The company named longtime Biogen Inc finance chief Paul Clancy as CFO in June, months after appointing former Baxalta executive Ludwig Hantson as CEO.

Like this: